Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836
Key facts
- Who runs it
- Osivax
- Where
- Belgium1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 117 people enrolled
- Started
- 22 Oct 2024
- Ended
- 2 Jun 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- OVX836 shot
- Record updated
- 6 June 2025
Who can take part
- Age
- 20 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Subject who voluntarily provides written informed consent to participate in the study
- Healthy male or female subjects, as determined by medical history and medical examination
- Subject compliant with the reproductive criteria for female participants
- Subjects who participated in the OVX836-002 or OVX836-003 studies
- Subjects aged 20 and 64 years, inclusive
- Reliable and willing to commit to participating for the duration of the study, and capable of following study procedures diligently
- Ability and technical capability to complete an eDiary
Who cannot take part
- Previous influenza vaccination within 6 months before the day of vaccination or planned to receive during the whole study period
- vaccination with an mRNA-based influenza vaccine including NP in its composition
- Other vaccination within 3 months prior to the day of study vaccination for live attenuated vaccines, or within 1 month prior to the day of study vaccination for non-live vaccines, at the exception of COVID vaccines which can be administered within 14 days before or after study vaccine administration
- Planning to receive other vaccines during the first 28 days following the study vaccine administration
- Administration of any investigational or non-registered drug or vaccine within 3 months prior to the administration of study vaccines, or planned administration of any such product during the entire study period
- History of receiving blood, blood components or immunoglobulins within 3 months prior to the day of vaccination or planned to receive such product during the whole study period
- History of alcohol or drug abuse that ceased less than 6 months before enrolment, current alcohol or drug abuse according to the Investigator's judgement), smoking habit of more than 10 cigarettes/day, or current vaping (nicotine consumption corresponding to more than 10 cigarettes/day)
- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months before the study vaccine administration. For corticosteroids, this will mean prednisone equivalent ≥20 mg/day. Inhaled, topical and intra-articular steroids are allowed
- Any known or suspected immunodeficient conditions
- Past or current history of significant autoimmune diseases, as judged by the Investigator
- Current history of uncontrolled medical illness such as diabetes, hypertension, heart, renal or hepatic diseases
- Known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)
- Presence of an acute febrile illness on the day of vaccination (oral temperature >38.0°C, temporary exclusion criterion)
- Past or current history of any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome
- Behavioral or cognitive impairment, or psychiatric disease that, in the opinion of the Investigator, may interfere with the subject's ability to participate in the study
- History of severe allergic reactions and/or anaphylaxis, or serious adverse reactions to vaccines or allergy to kanamycin or any other component of the vaccine
- Individuals with a history of any illness that, in the opinion of the Investigator, could potentially interfere with the results of the study or pose additional risk to the subjects by participating in the study
- Current or past malignancy, unless completely resolved for >5 years (except non-metastatic basal cell carcinoma which has been completely resected)
- Subjects with a body mass index (BMI) ≤18 kg/m² or ≥35 kg/m² on the day of vaccination
- Pregnant or lactating woman
- Female planning to become pregnant or planning to discontinue contraceptive precautions until the end of the trial
- Participants with extensive tattoos covering deltoid regions on both arms that would preclude the assessment of local reactogenicity
- Any contraindication to IM administration, as judged by the Investigator
- Sponsor employees or Investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted, including children of newly composed families
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This phase 2a is designed to evaluate the anamnestic response of a booster dose (either 180 µg or 480 µg) of OVX836 influenza vaccine administered intramuscularly to participants vaccinated three to five years ago in OVX836-002 or OVX836-003 studies. Participants who had received a placebo or Influvac Tetra® in previous studies would serve as controls and would receive the highest dose of OVX836 vaccine (480 µg) as a primary vaccination.
The 2 groups in the trial
- OVX836 - 180μg dose levelTreatment being tested
180 µg dose of an adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus.
Treatment: OVX836 shot
- OVX836 - 480μg dose levelTreatment being tested
480 µg dose of an adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus.
Treatment: OVX836 shot
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Phase 2a, Single Center, Randomized, Double-blind, Study to Evaluate the Immunogenicity and Safety of One Single Administration of OVX836 Influenza Vaccine at Two Dose Levels (180µg or 480μg) Given Intramuscularly (IM), Either as a Booster or a Primary Vaccination in Healthy Adults Previously Administered With OVX836, Influvac Tetra® or Placebo in the OVX836-002 (EudraCT Number: 2019-002939-28) and OVX836-003 (EudraCT Number: 2021-002535-39) Studies.
- Record updated
- 6 June 2025